Drugs & Targets FDA approves crizotinib for ALK-positive inflammatory myofibroblastic tumor July 15, 2022Vol.48 No.28
Drugs & Targets FDA accepts BLA for mosunetuzumab in relapsed or refractory follicular lymphoma July 08, 2022Vol.48 No.27
Drugs & Targets AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, TNB-486 July 08, 2022Vol.48 No.27
Drugs & TargetsFree FDA approves Breyanzi in relapsed or refractory large B-cell lymphoma after one prior therapy July 01, 2022Vol.48 No.26
Drugs & TargetsFree EMA CHMP adopts positive opinion for Lynparza in germline BRCA-mutated, HER2-negative high-risk early breast cancer July 01, 2022Vol.48 No.26
Drugs & TargetsFree Community Health Network, GRAIL to offer Galleri MCED test in Central Indiana July 01, 2022Vol.48 No.26
Drugs & TargetsFree FDA issues draft guidance on patient-focused drug development July 01, 2022Vol.48 No.26
Drugs & Targets FDA grants accelerated approval to Tafinlar + Mekinist in unresectable or metastatic solid tumors with BRAF V600E mutation June 24, 2022Vol.48 No.25
Drugs & Targets FDA grants Fast Track designation to IK-930 in unresectable NF2-deficient mesothelioma June 24, 2022Vol.48 No.25
Drugs & Targets Cullinan Oncology, Taiho Pharmaceuticals complete agreement to develop and commercialize CLN-081/TAS6417 June 24, 2022Vol.48 No.25
